At a glance
ClinicalIndex Comparison RecordN/ACompleted· 20 enrolled
Drug / intervention
Tranexamic aciddrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Intraoperative Use of Tranexamic Acid in Reducing Blood Loss During Telescoping Nail Application in Osteogenesis Imperfecta - Randomized Control Trials
In Brief
A clinical study evaluating Tranexamic acid for Osteogenesis Imperfecta. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The aim of this study is to assess the effective of intraoperative use of tranexamic acid in reducing blood loss during telescoping nail application in cases of osteogenesis imperfecta.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteogenesis Imperfecta
CountriesEgypt
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
First PostedApr 2022
Enrollment StartMay 2022
Primary CompletionNov 2023
TodayJul 2026
First PostedApr 11, 2022
Enrollment StartMay 1, 2022
Primary CompletionNov 30, 2023
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 4.2 years ago
Interventions
Tranexamic aciddrug
Tranexamic acid (TXA) is an antifibrinolytic drug that has been shown to be effective in reducing blood loss and the need for transfusions after several orthopaedic surgeries.